資源描述：
《多指標(biāo)聯(lián)合檢測在小細(xì)胞肺癌診斷中的應(yīng)用價值研究》由會員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在學(xué)術(shù)論文-天天文庫。
1、授予單位代碼10089m學(xué)號或申請?zhí)?0434HebeiMedicalUniversity碩士學(xué)位論文在職科學(xué)學(xué)位多指標(biāo)聯(lián)合檢測在小細(xì)胞肺癌診斷中的應(yīng)用價值研究學(xué)位申請人：趙維川導(dǎo)師：張金艷教授專業(yè)：臨床檢驗診斷學(xué)二級學(xué)院：第四醫(yī)院2015年3月河北醫(yī)科大學(xué)學(xué)位論文使用授權(quán)及知識產(chǎn)權(quán)歸屬承諾本學(xué)位論文在導(dǎo)師（或指導(dǎo)小組）的指導(dǎo)下，由本人獨(dú)立完成。本學(xué)位論文研宄所獲的研究成果，其知識產(chǎn)權(quán)歸河北醫(yī)科大學(xué)所有。河北醫(yī)科大學(xué)有權(quán)對本學(xué)位論文進(jìn)行交流、公開和使用。凡發(fā)表與學(xué)位論文相關(guān)的論文，第一署名單位為河北醫(yī)科大學(xué)
2、，試驗材料、原始數(shù)據(jù)、申報的專利等知識產(chǎn)權(quán)均歸河北醫(yī)科大學(xué)所有。否則，承擔(dān)相應(yīng)的法律責(zé)任。研宄生簽名知良叫導(dǎo)師簽章:務(wù)/^p二級學(xué)院頷梟簽章‘)ir年r月^^i賤:‘1??>?河北醫(yī)科大學(xué)研究生學(xué)位論文獨(dú)創(chuàng)性聲明本論文是在導(dǎo)師指導(dǎo)下進(jìn)行的研宄工作及取得的研宄成果，除了文中特別加以標(biāo)注和致謝等內(nèi)容外，文中不包含其他人巳經(jīng)發(fā)表或撰寫的研究成果，指導(dǎo)老師對此進(jìn)行了審定。本論文由本人獨(dú)立撰寫，文責(zé)自負(fù)。研宄生簽名^導(dǎo)師簽章：丨年/月w曰目錄中文摘要·································
3、············································1英文摘要·············································································2研究論文多指標(biāo)聯(lián)合檢測在小細(xì)胞肺癌診斷中的應(yīng)用價值研究前言·············································································5材料與方法·················
4、···················································5結(jié)果·············································································9附圖·············································································11附表·········································
5、····································13討論·············································································16結(jié)論·············································································19參考文獻(xiàn)····················································
6、···················19綜述腫瘤標(biāo)志物在小細(xì)胞肺癌診斷中應(yīng)用情況的研究進(jìn)展···········21致謝···················································································30個人簡歷·············································································31中文摘要多指標(biāo)聯(lián)合檢測在小細(xì)胞肺癌診斷中的應(yīng)用價值研究
7、摘要目的：探討血清腫瘤標(biāo)志物CEA、NSE和ProGRP與免疫組化指標(biāo)Syn、CD56、CgA，Ki-67在小細(xì)胞肺癌診斷中的關(guān)系。方法：應(yīng)用電化學(xué)發(fā)光技術(shù)和化學(xué)發(fā)光技術(shù)檢測48例小細(xì)胞肺癌患者血清標(biāo)志物CEA、NSE和ProGRP的濃度；采用MaxVision免疫組化技術(shù)檢測Syn、CD56、CgA，Ki-67；用χ2檢驗、兩獨(dú)立樣本非參數(shù)檢驗、等級相關(guān)Spearman’s檢驗分析結(jié)果。結(jié)果：1小細(xì)胞肺癌免疫組化Syn、CD56、CgA表達(dá)陽性率高于血清CEA，P<0.001差異有統(tǒng)計學(xué)意義。免疫組化Sy
8、n、CD56、CgA表達(dá)陽性率與血清NSE、ProGRP比較，無顯著性差異。2Ki-67增殖程度與血清腫瘤標(biāo)志物CEA、NSE、ProGRP等濃度之間均有負(fù)相關(guān)關(guān)系，r值分別為-0.445、-0.065、-0.130；P值分別為<0.001、0.001、<0.001。P值均＜0.05有統(tǒng)計學(xué)意義。3局限期與廣泛期免疫組化指標(biāo)陽性率表達(dá)無統(tǒng)計學(xué)意義；廣泛期血清腫瘤標(biāo)志物CEA、NSE、ProGRP濃度均高于局限期，
